SuzanneLentzschMD

PubMed

• 733 citations
  Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
  Faith E. Davies, Noopur Raje, Teru Hideshima, Suzanne Lentzsch, Gloria Young
  Blood. 2001-07-01
• 48 citations
  Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
  Shahzad Raza, Rachael A Safyan, Suzanne Lentzsch
  Current Cancer Drug Targets. 2017-10-31
• 63 citations
  Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia
  Rekha Pal, Sara A. Monaghan, Andrea L. Cortese Hassett, Markus Y. Mapara, Peter H. Schafer
  Blood. 2010-01-21

Journal Articles

• Disrupted Radial and Tibial Microarchitecture in Patients with Monoclonal Gammopathy of Undetermined Significance  
  E Shane, E M Stein, S Lentzsch, J Fu, Osteoporosis international
• Selinexor plus Low-Dose Bortezomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma  
  Suzanne Lentzsch, Cristina Gasparetto, Blood
• Beyond NEOD001 for Systemic Light-Chain Amyloidosis  
  Suzanne Lentzsch, Cindy Varga, Blood
• Immunomodulatory Drugs Downregulate IKZF1 Leading to Expansion of Hematopoietic Progenitors with Concomitant Block of Megakaryocytic Maturation  
  Markus Y Mapara, Sara A Monaghan, Suzanne Lentzsch, Haematologica
• Whole-Body Low-Dose Computed Tomography and Advanced Imaging Techniques for Multiple Myeloma Bone Disease  
  Pianko MJ, Terpos E, Roodman GD, Chaitanya R. Divgi, Sonja Zweegman, Jens Hillengass, and Lentzsch S, Clin Cancer Res, 1/1/2014
• Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group  
  Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazu..., Leukemia, 1/27/2013
• Longitudinal one marrow evaluations for myelodysplasia in patients with myeloma before and after treatment with lenalidomide  
  Monaghan SA, Dai L, Mapara M, Normolle DP, Gollin SM, Lentzsch S, Leukemia, 1/27/2013
• International Myeloma Working Group Recommendations for the treatment of multiple myeloma-related bone disease  
  Terpos E, Morgan G, Dimopoulos MA, Drake MT, Lentzsch S, Raje N, Sezer O, Garcia-Sanz R, Shimizu K, Turesson I, Reiman T, Jurczyszyn A, Merlini G, Spencer A, Leleu X, ..., J Clin Oncol, 1/1/2013
• A phase 2 multicentre study of siltuximadb and anti-interleukin-6- monoclonal antibody in patients with relapsed or refractory multiple myeloma  
  Voorhees PM, Manges RF, Sonneveld P, Jagannath S, Somlo G, Krishnan A, Lentzsch S, Frank RC, Zweegman S, Wijermans PW, Orlowski RZ, Kranenburg B, Hall B, Casneuf T, Qi..., Br J Haematol, 1/1/2013
• Risk of Secondary Primary Malignancies in Maintenance Therapy for Multiple Myeloma  
  Schecter J, Lentzsch S, Int. J. hematol.oncol, 1/1/2013
• Pomalidomide is strongly antiangiogenic and teratogenic in relevant animal models  
  D'Amato RJ, Lentzsch S, Rogers MS, Proc Natl Acad Sci U S A, 1/1/2013
• Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initioal treatment for patients with chronic lymphocytic...  
  Foon Ka, Mehta D, Lentzsch S, Kropf P, Marks S, Lenzner D, Pietragallo L. Sulecki M, Tarhini A, Boyiadzis M, Blood, 1/29/2012
• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study  
  Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé..., Leukemia, 1/26/2012
• Bisphosphonates as antimyeloma drugs  
  Modi ND, Lentzsch S, Leukemia, 1/26/2012
• Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results o...  
  Lentzsch S, O’Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara MY, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA, Blood, 1/17/2012
• Lenalidomide-induced upregulation of CXCR4 in CD34+ hematopoietic cells, a potential mechanism of decreased hematopoietic progenitor mobilization  
  Li S, Fu J, Ma H, Mapara M, Lentzsch S, Leukemia, 1/1/2012
• The application and biology of immunomodulatory drugs (IMiDs) in cancer  
  Pan B, Lentzsch S, Pharmacol Ther, 1/1/2012
• IMiD immunomodulatory compounds block C/EBP{beta} translation through eIF4E down-regulation resulting in inhibition of MM  
  Li S, Pal R, Monaghan SA, Schafer P, Ouyang H, Mapara M, Galson DL, Lentzsch S, Blood, 1/1/2011
• Multiple Myeloma  
  Modi N, Roodman GD, Lentzsch S, 1/1/2011
•  
  Ma H, Lu C, Ziegler J, Liu A, Sepulveda A, Okada H, Lentzsch S, Mapara MY, J Clin Invest, 1/1/2011
• Metastatic breast cancer or multiple myeloma?  
  Hough B, Brufsky A, Lentzsch S, J Oncol, 1/1/2010
• Potential Role of IMiDs and Other Agents as Therapy for Myeloma Bone Disease in Myeloma Bone Disease, Ed G D Roodman, Humana Press, 199-209  
  Lentzsch S, Current Clinical Oncology, 1/1/2010
• The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group  
  Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group, Leukemia, 1/1/2010
• Cell-based and cytokine-directed chemical screen to predict drug potency and anti-multiple myeloma activities  
  Feng R, Rios JA, Onishi T, Lokshin A, Gorelik E, Lentzsch S, Leukemia Research, 1/1/2010
• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and ...  
  Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson ..., Leukemia, 1/1/2010
• Join now to see all

Books/Book Chapters

• Genetic and Molecular Epidemiology of Multiple Myeloma 
  Chapter: Cap-Dependent Protein Translation Initiation in Multiple Myeloma: An Attractive Target for Therapy 
  Lentzsch S, Fu J, Li SSpringer Science2013
• Multiple Myeloma - A New Era of Treatment Strategies 
  Chapter: Management of Complications of Multiple Myeloma 
  Lentzsch SEditors: Podar K and Anderson KC.Bentham Science Publishers2011
• Oxidative Stress in Cancer Biology Therapy 
  Chapter: Histone Deacetylase Inhibitors, Oxidative Stress, and Multiple Myeloma Therapy 
  Feng R, Lentzsch SEditors: Spitz Douglas, R.Springer Science, New York, NY2011

Abstracts/Posters

• Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Single Arm, Prospective, Open-Label Phase II Trial to Evaluate the Efficacy of Isatuximab in Patients with Monoclonal Gammopathy of Renal Significance
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Excellent Survival and Immune Reconstitution Following Matched/Mismatched Unrelated and Mismatched Related Transplantation in Adult Patients with Sickle Cell Disease: ...
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Combination Chemotherapy with Carfilzomib, Bendamustine and Dexamethasone Is Highly Active for Therapy of Newly Diagnosed Multiple Myeloma-Results of Single Center Pha...
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Role of MMP-13 in Graft-Versus-Host Disease
  Suzanne Lentzsch, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• New Drug Classess in Plasma Cell Disorders
  Suzanne Lentzsch, Susanna Miao, Jordan Schecter, Kent Griffith, Daniel Normolle, Markus Mapara, Robert Redner, Nicholas Villanueva, ASCO, 1/1/2015
• Lendalidomide and low-dose dexamethasone (Ld) is equivalent to Ld plus autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM): Results of a ...
  Suzanne Lentzsch, Susanna Miao, Jordan Schecter, Kent Griffith, Daniel Normolle, Markus Mapara, Robert Redner, Nicholas Villanueva, ASCO, 1/1/2015
• IMiD Compounds Affect the Hematopoiesis Via CRBN Dependent Degradation of IKZF1 Protein in CD34+ Cells
  Shirong Li, Jing Fu, Ph, Markus Mapara, and Suzanne Lentzsch, ASH Annual Meeting, 1/1/2014
• Pomalidomide Induces Mir-125b with Subsequent Downregulation of P53 in CD34+cells Conferring Decreased Apoptosis: A Potential Mechanism of Secondary Primary Malignancies
  Yijie Zheng, Shirong Li, Jing Fu, Markus Mapara, and Suzanne Lentzsch, ASH Annual Meeting, 1/1/2014
• Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light Chain (AL) Amyloidosis
  Suzanne Lentzsch, Raymond L. Comenzo, Keren Osman, Kevin Zikaras, Daniel Backenroth, Wei-Yann Tsai, Vaishali Sanchorawala and Heather Landau, ASH Annual Meeting, 1/1/2014
• A Phase I Dose-Escalation Study of Carfilzomib in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis
  Adam D. Cohen, Emma C. Scott, Michaela Liedtke, Jonathan L. Kaufman, Heather Landau, David H. Vesole, Christina L. Gomes, Cristina Gasparetto, Suzanne Lentzsch, Michae..., ASH Annual Meeting, 1/1/2014
• Absence of Mutaion in Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes in Myeloma Cells and Patients and its Clinical Significance
  Thakurta A, Gandhi A, Waldman M, Bjorklund C, Lentzsch S, Schey S, Calle Y, Chelliah R, Orlowski R, Madan A, Ning Y, Mendy D, Lopez-Girona A, Schafer P, Chopra R, ASH Annual Meeting, 1/1/2013
• Matrix Metallopeptidase 13 (MMP13) induces osteolytic lytic lesions independent from its catalytic activity
  Fu J, Li S, Feng R, Sabeth F, Roodman D, Mapara M, Weiss S, Lentzsch S, 14th International Myeloma Workshop, 1/1/2013
• Safety and efficacy of Pomalidomide (POM) with or without Low-dose dexamethasone (lodex) in relapsed and refractory multiple myeloma (RRMM) long term follow-up of pati...
  Richardson P, Siegel D, Vij R, Hofmeister C, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Chen M, Zak..., EHA, 1/1/2013
• Long-Term safety and efficacy of Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled...
  Richardson P, Siegel D, Vij R, Hofmeister C, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Chen M, Zak..., ASCO, 1/1/2013
• Long-Term Safety and Efficacy of Pomalidomide with or without Low dose Dexamethasone in Relapsed and Refractory Multiple Myeloma patients Enrolled in the MM-002 Phase ...
  Siegel D, Richardson P, Vij R, Hofmeister C, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Chen M, Zaki..., EHA, 1/1/2013
• Bialas Phase I/II Dose Expansion Of a Multi-Center Trial Of Carfilzomib and Pomalidomide With Dexamethasone (Car-Pom-d) In Patients With Relapsed/Refractory Multiple M...
  Jatin Shah Stadtmauer, E, Rafat Abonour, Adam D. Cohen, William Bensinger, Cristina Gasparetto, Jonathan L. Kaufman, Suzanne Lentzsch, Dan T. Vogl, Robert Z. Orlowski..., ASH Annual Meeting, 1/1/2013
• Pathologic and Clinical Features Of CD30+ Post-Transplant Lymphoproliferative Disorders: A Large Retrospective Single Institutional Study
  Jordan M. Schecter, Daniela Hoehn, Philip Imus, Eleonora Alma, Suzanne Lentzsch, Bachir Alobeid, Manuela Orjuela, Owen A. O'Connor, and Govind Bhaga, ASH Annual Meeting, 1/1/2013
• Lenalidomide and Dexamethasone Alone Is Equivalent To Lenalidomide and Dexamethasone With Autologous Stem Cell Transplant In Newly Diagnosed Multiple Myeloma: Interim ...
  Jordan M. Schecter, Kristen Kipps, Amy O'Sullivan, Kent A. Griffith, Daniel Normolle, Markus Mapara, Robert Redner, MD6 and Suzanne Lentzsch, PhD, ASH Annual Meeting, 1/1/2013
• Knockdown Of Matrix Metalloproteinase 13 (MMP13) In 5TGM1 Multiple Myeloma Cells Inhibits Development Of Lytic Bone Lesions In Vivo
  Jing Fu, Li, S, Huihui Ma, G. David Roodman, Markus Y. Mapara, MD PhD4*, Stephen J Weiss, MD5 and Suzanne Lentzsch, MD, ASH Annual Meeting, 1/1/2013
• Inducible Silencing Of eIF4E Using a Tet-On System Results In Myeloma Growth In Vivo That Correlates With eIF4E Expression
  Li, S, Jing Fu, Jordan M. Schecter, Caisheng Lu, Markus Y. Mapara, and Suzanne Lentzsch, ASH Annual Meeting, 1/1/2013
• Join now to see all

Lectures

• Untangling Amyloidosis 2018 
  60th American Society of Hematology Annual Meeting - 11/30/2018
• Bone Disease in Multiple Myeloma 
  ENDO 2018: 100th Endocrine Society Annual Meeting - Chicago, Illinios - 03/17/2018
• What is Optimal maintenance therapy duration for a newly diagnosed multiple myeloma patients completing induction 
  New York, NY - 1/1/2015
• Should consolidation therapy and minimal residual disease testing be used for monitoring and treatment 
  New York, NY - 1/1/2015
• New Insights Proteasome Inhibitors and IMiDs in Hematopoietic cells 
  Boston, MA - 1/1/2015
• Evolving Treatment Paradigms in Relapsed/Refractory Multiple Myeloma: What Defines Optimal Therapy? 
  Englewood, NJ - 1/1/2015
• IMiDs induce Degradation of IKZF1 in Hematopoietic Progenitors 
  Boston, MA - 1/1/2015
• What’s New in Amyloidosis 
  New York, NY - 1/1/2014
• Update on transplant-ineligible patients: Which regimens are best? 
  New York, NY - 1/1/2014
• Annual Update & Intensive Review of Internal Medicine 
  New York, NY - 1/1/2014
• The other stem cell in Myeloma: CD34+ mobilization, exhaustion, and SPMs 
  New York, NY - 1/1/2013
• MMP13 & Osteoclastogenesis in Multiple Myeloma 
  New York, NY - 1/1/2013
• Role of MMP13 in Multiple Myeloma and Bone Disease 
  New York, NY - 1/1/2012
• Immunomodulatory Derivatives of Thalidomide 
  New York, NY - 1/1/2012
• Immunomodulatory Derivatives induce self-renewal of hematopoietic progenitors and block of maturation of megakaryocytes 
  Scottsdale, AZ - 1/1/2012
• Intracellular targets of Immunomodulatory derivative of Thalidomide 
  Kyoto, Japan - 1/1/2012
• Mechanisms of complications to targeted therapies 
  Orlando, FL - 1/1/2011
• Immunomodulatory Derivatives of Thalidomide - Friends and Foes in the Treatment of Multiple Myeloma! 
  New York, NY - 1/1/2011
• Effects of IMiDs on Granulocytic Maturation 
  New York, NY - 1/1/2011
• New Treatments and How Best to Use Them in Lymphoma and Myeloma 
  New York, NY - 1/1/2011
• Immunomodulatory Derivatives of Thalidomide - Friends and Foes in the Treatment of MM, Ground Rounds 
  New York, NY - 1/1/2011
• Immunomodulatory Derivatives induce self-renewal of hematopoietic progenitors and bl0ck of maturation of megakaryocytes 
  London, UK - 1/1/2011
• IMids and Transcription 
  London, UK - 1/1/2011
• Combination of Bendamustine, Lenalidomide, and Dexamethasone in Patients with Refractory or Relapsed MM Is Safe and Highly Effective: Results of Phase I Clinical Trial 
  1/1/2011
• Mechanisms of complications IMiDs 
  1/1/2011
• Join now to see all

Other

• Treatment Combination Offers New Option for Patients with Advanced Multiple Myeloma 
  Suzanne Lentzsch, UPMC Physician Resources
  http://blogs.upmcphysicianresources.com/2011/treatment-combination-offers-new-option-for-patients-with-advanced-multiple-myeloma-upci-researchers-find/
• Multiple Myeloma and Bone Disease 
  Suzanne Lentzsch, Wego Health
  http://sharinghub.wegohealth.com/multiple-myeloma-and-your-bones/40-treating-multiple-myeloma-bone-disease
• Managing Myeloma a Professional Resource for Multiple Myeloma 
  Suzanne Lentzsch
  http://www.managingmyeloma.com/knowledge-center/clinical-trials/highlighted-trials-2013/804-phase-ii-trial-with-elotuzumab-plus-lenalidomide-and-low-dose-dexamethasone-in
• A Randomized Clinical Trial of Lenalidomide and Dexamethasone with and without Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma: Int... 
  Suzanne Lentzsch
  http://www.youtube.com/watch?v=T2mPFnC0Prg
  1/1/2013
• Combination of Bendamustine, Lenalidomide, and Dexamethasone (BLD) in Patients with Refractory or Relapsed Multiple Myeloma Is Safe and highly Effective: Results of P... 
  Suzanne Lentzsch
  http://myeloma.org/ArticlePage.action?articleId=3578
  1/1/2011
• Genetic and Molecular Epidemiology of Multiple Myeloma 
  Lentzsch S
• A Future Without Cancer 
  Suzanne Lentzsch
• Current Strategies in the Management of Bone Related Complication in Cancer Patients 
  Suzanne Lentzsch, Baylor Health Care System
  www.cmebaylor.org
• Current Strategies in the Management of Bone Related Complication in Cancer Patients Video Interview: Cancernet 
  Suzanne Lentzsch
  http://www.cancer.net/
• ASH Bridge Grants Announced in Conjunction with Rally for Medical Research 
  Suzanne Lentzsch, Youtube
• Leukemia Lymphoma Society Man & Woman of the Year 2014 
  Suzanne Lentzsch
  http://vimeo.com/llsnycchapter/mwoy2015
• Management of Bone Disease/Clinical Trials and New Drugs 
  Suzanne Lentzsch
  http://www.youtube.com/watch?v=pvoUZcewadk
• Innovative Approaches to Therapy For Transplant-Ineligible Patients With Myeloma 
  Suzanne Lentzsch
  http://www.medscape.org/viewarticle/831384
• Critical Decisions for Optimal Treatment of Multiple Myeloma 
  Suzanne Lentzsch
  www.clinicalcareoptions.com
• Join now to see all